RRM2/GCH1 signaling decreased cisplatin sensitivity in cervical cancer by modulating the ferroptosis process.

RRM2 plays roles in the evaluation and outcome prediction of cervical cancer, potentially impacting cisplatin sensitivity through regulation of ferroptosis. This investigation provides novel insights into the tumorigenic functions of RRM2, highlighting its potential use as a prognostic biomarker in cervical carcinoma.